Vertex Pharmaceuticals Inc VRTX
News
Vertex Reports First Quarter 2024 Financial Results
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex's stock climbs as non-opioid pain treatment advances
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion — Update
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
Vertex to Announce First Quarter 2024 Financial Results on May 6
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
Thinking about trading options or stock in Tesla, Energy Transfer, Paramount Global, Vertex Pharmaceuticals, or Broadcom ?
Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
Vertex Pharmaceuticals Cystic Fibrosis Drug Gets Positive Opinion in EU For Treatment in Infants